Edgewise Therapeutics, Inc. — Director's Dealing 2021

Mar 31, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edgewise Therapeutics, Inc. (EWTX)
CIK: 0001710072
Period of Report: 2021-03-30

Reporting Person: Novo Holdings A/S (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-30	COMMON STOCK	C	4962207	—	Acquired	4962207	Direct
2021-03-30	COMMON STOCK	P	625000	$16.00	Acquired	5587207	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-30	SERIES B-1 CONVERTIBLE PREFERRED STOCK	$	C	2359440	Disposed		COMMON STOCK (2359440)	Direct
2021-03-30	SERIES B-2 CONVERTIBLE PREFERRED STOCK	$	C	1952439	Disposed		COMMON STOCK (1952439)	Direct
2021-03-30	SERIES C CONVERTIBLE PREFERRED STOCK	$	C	650328	Disposed		COMMON STOCK (650328)	Direct

Footnotes

F1: Each share of Series B-1 Convertible Preferred Stock, Series B-2 Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date.

F2: Represents a purchase from the underwriters in the Issuer's initial public offering.